KUALA LUMPUR, Feb 24 (Bernama) -- Public-listed healthcare company, Malaysian Genomics Resource Centre Berhad (MGRC), and its subsidiary, pathology services company Clinipath (Malaysia) Sdn Bhd (Clinipath) today announced the availability of Dtect Prostate+, an affordable genetic screening test that examines key genes associated with prostate cancer.
 
Prostate cancer (PCa) is the most common cancer affecting adult men. Typical symptoms of PCa are burning or pain during urination, difficulty urinating or trouble starting and stopping while urinating, frequent urges to urinate at night, loss of bladder control, decreased flow or velocity of the urine stream, and blood in urine. Early stages of PCa are often not symptomatic which makes it a difficult disease to detect early.
 
In 2018, the Ministry of Health Malaysia published the MySCan study on cancer incidence and survival rates. From the study, the incidence rate was observed to increase with age, especially above 55 years. The mortality rate is 59%. Most importantly, the study found that early detection and treatment of PCa (at Stage 1) led to a 5-year relative survival rate of 97.3%.
 
Genetic screening can identify genetic predispositions to PCa. Positive results from Dtect Prostate+ may identify a need for regular, pathology surveillance to catch the disease early when it is easiest to treat. Positive results may also be useful to encourage positive lifestyle changes to mitigate the risk of PCa occurring.
 
MGRC and Clinipath continue to work together to make comprehensive pathology services, and the latest in genetic testing available to doctors with a view to improving the lives of patients in Malaysia and the region.
 
About Malaysian Genomics Resource Centre Berhad
 
MGRC was a pioneer in genome sequencing, bioinformatics analysis and genetic screening services. Since 2004, MGRC had developed extensive pipelines in the sequencing and analysis of human, animal, plant and microbial genomes for clients worldwide. Today, MGRC is focused on merging the latest in genetic testing with pathology to enable doctors to provide personalised healthcare for their patients.
 
About Clinipath (Malaysia) Sdn Bhd
 
Clinipath is one of Malaysia’s largest independent pathology service providers with a nationwide network of 18 branches. It offers a complete range of fast, accurate and reliable pathology testing services. It has been ISO 15189 accredited since 2010. Clinipath is a wholly-owned subsidiary of public-listed MGRC. 
 
Source: Malaysian Genomics Resource Centre Berhad 

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Shawn Keng
Tel: +6014-9685808
Email: enquiries@mgrc.com.my
 
 
--BERNAMA